Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Protagonist Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Protagonist Therapeutics's price to sales ratio was 30.9× on Nov 11, 2026, against 26.9× a year earlier. Over the last 5 years it ranged from 5.2× to 143.3×, with a median of 24.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 30.9× | +4.9 |
| 2025 | Dec 31, 2025 | 26.1× | +19.0 |
| 2024 | Dec 31, 2024 | 7.1× | −34.9 |
| 2023 | Apr 28, 2023 | 42.0× | +26.7 |
| 2022 | Dec 30, 2022 | 15.3× | −51.6 |
| 2021 | Dec 31, 2021 | 66.8× | +55.0 |
| 2019 | Jul 31, 2019 | 11.9× | +7.8 |
| 2018 | Dec 31, 2018 | 4.1× | – |
See a number that looks wrong?